US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polyrizon Ltd.

14.20

+0.32002.31%

Volume:37.95K

Turnover:504.57K

Market Cap:14.79M

PE:-19.96

High:14.37

Open:14.37

Low:12.40

Close:13.88

52wk High:2,235.00

52wk Low:2.88

Shares:1.04M

Float Shares:996.80K

Volume Ratio:2.11

T/O Rate:3.81%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7114

ROE:-12.20%

ROA:-22.25%

PB:0.81

PE(LYR):- -

Loading ...

Overview Company News Filings

Polyrizon signs MOU to buy up to 20% of Colugo for up to USD 6 million

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced Evtol Drones for Defense and Urban Air Mobility Applications

THOMSON REUTERS

Polyrizon Ltd. Director Liat Sidi Files Initial Beneficial Ownership Statement

Polyrizon Ltd. Chief Science Officer Eyal S. Ron filed initial beneficial ownership statement

Polyrizon Ltd. Director Yehonatan Zalman Vinokur Files Initial Beneficial Ownership Statement

Polyrizon Ltd. files Form 3 initial beneficial ownership statement for Director Carmel Liron

Polyrizon Ltd. files initial beneficial ownership statement for CTO Tidhar Turgeman

Polyrizon Ltd. director Oz Adler files initial beneficial ownership statement

Polyrizon Ltd. files Form 3 beneficial ownership statement for CEO Tomer Izraeli

Polyrizon Ltd. CFO Nir BenYosef files initial beneficial ownership statement

Polyrizon signs agreement with research organization for clinical development

Polyrizon signs agreement with global preclinical CRO for ISO 10993 biocompatibility studies

Polyrizon Signs an Agreement With Leading Global Preclinical Cro as Part of Clinical Development Program

THOMSON REUTERS

Polyrizon Produces GMP Clinical Trial Material Batch With Eurofins CDMO AmatsiAquitaine

Polyrizon Announces Gmp Manufacturing of Clinical Trial Material (Ctm) With Eurofins CDMO Amatsiaquitaine S.a.s for Planned U.S. Clinical Study

THOMSON REUTERS

BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug

Polyrizon Reports Study Showing Improved Nasal Deposition for Its Naloxone Formulation Versus Commercial Product

Polyrizon Announces Successful Study of Its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

THOMSON REUTERS

Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PLRZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":14.2,"timestamp":1774377678166,"preClose":13.88,"halted":0,"volume":37945,"delay":0,"changeRate":0.023054755043227557,"floatShares":996800,"shares":1041700,"eps":-0.71144193,"marketStatus":"Trading","change":0.32,"latestTime":"03-24 14:45:33 EDT","open":14.37,"high":14.37,"low":12.4,"amount":504566.27617,"amplitude":0.141931,"askPrice":14,"askSize":1,"bidPrice":13.43,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-0.71144193,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774382400000},"marketStatusCode":2,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":13.88,"preHourTrading":{"tag":"盘前","latestPrice":13.5,"preClose":13.88,"latestTime":"09:27 EDT","volume":1398,"amount":19655.589216,"timestamp":1774358875868,"change":-0.38,"changeRate":-0.027378,"amplitude":0.070605},"postHourTrading":{"tag":"盘后","latestPrice":14.3,"preClose":14.3,"latestTime":"18:35 EDT","volume":95,"amount":1318.43,"timestamp":1774305305804,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.107903},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":996800,"roa":"-22.25%","roe":"-12.20%","lyrEps":0,"volumeRatio":2.107903,"shares":1041700,"dividePrice":0,"high":14.37,"amplitude":0.141931,"preClose":13.88,"low":12.4,"week52Low":2.88,"pbRate":"0.81","week52High":2235,"institutionHeld":0,"latestPrice":14.2,"committee":0.99005,"eps":-0.71144193,"divideRate":0,"volume":37945,"delay":0,"ttmEps":-0.71144193,"open":14.37,"prevYearClose":8.49,"prevWeekClose":13.7,"prevMonthClose":12.49,"prevQuarterClose":8.49,"fiveDayClose":13.6,"twentyDayClose":14,"sixtyDayClose":7.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-03-20","current":-20.100024,"percent":0.130058,"low":-29.515607,"twenty":-13.87234,"median":-6.068669,"eighty":-2.429444,"high":-0.011381,"avg":-8.107917,"sd":6.818421,"marketCap":21518271},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571},{"date":"2026-02-06","current":-17.471559,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"marketCap":19812748},{"date":"2026-02-13","current":-19.664289,"twenty":-11.445985,"median":-5.322255,"eighty":-2.161828,"marketCap":22299304},{"date":"2026-02-20","current":-19.158274,"twenty":-11.780175,"median":-5.500199,"eighty":-2.356399,"marketCap":21725483},{"date":"2026-02-27","current":-19.24261,"twenty":-12.048622,"median":-5.587228,"eighty":-2.377712,"marketCap":21821120},{"date":"2026-03-06","current":-19.130163,"twenty":-12.337157,"median":-5.805751,"eighty":-2.404957,"marketCap":21693605},{"date":"2026-03-13","current":-21.491564,"twenty":-13.089202,"median":-5.977481,"eighty":-2.428961,"marketCap":24371434},{"date":"2026-03-20","current":-18.975548,"twenty":-13.87234,"median":-6.068669,"eighty":-2.429444,"marketCap":21518271}],"updateTime":1774340412774},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621062014","title":"Polyrizon signs MOU to buy up to 20% of Colugo for up to USD 6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062014","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062014?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:47","pubTimestamp":1774356435,"startTime":"0","endTime":"0","summary":"Polyrizon signed a non-binding MOU with shareholders of Colugo to acquire up to a 20% stake in the company.The aggregate purchase price is up to USD 6.0 million, payable in cash or via issuance of Polyrizon shares.Two Colugo shareholders would sell approximately 20% of Colugo’s fully diluted share capital to Polyrizon.The transaction is expected to close within 7 days after conditions are met, including a definitive agreement and corporate approvals.The MOU terminates upon written notice by either party or on September 30, 2026 if the transaction has not closed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8bMndj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","BK4139","LU2210150020.SGD","BK4585","SG9999014013.SGD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2621062099","title":"Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced Evtol Drones for Defense and Urban Air Mobility Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062099?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:47","pubTimestamp":1774356420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA31CH51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2620324472","title":"Polyrizon Ltd. Director Liat Sidi Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620324472","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620324472?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:45","pubTimestamp":1773830713,"startTime":"0","endTime":"0","summary":"Polyrizon director Liat Sidi filed an initial statement of beneficial ownership on 03/18/2026. The filing reported direct beneficial ownership of 3,648 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5bjDbT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"gpt_icon":0},{"id":"2620232102","title":"Polyrizon Ltd. Chief Science Officer Eyal S. Ron filed initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232102","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232102?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:44","pubTimestamp":1773830673,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership by Eyal Ron, Chief Science Officer. Ron reported direct beneficial ownership of 1,459 ordinary shares. Ron also reported options to purchase 8 ordinary shares at a USD 1,018.3 exercise price. He additionally reported options to purchase 10 ordinary shares at a USD 1,699.3 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7vngbZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"gpt_icon":0},{"id":"2620192232","title":"Polyrizon Ltd. Director Yehonatan Zalman Vinokur Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620192232","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620192232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830591,"startTime":"0","endTime":"0","summary":"Polyrizon director Yehonatan Zalman Vinokur filed an Initial Statement of Beneficial Ownership on March 18, 2026. The filing reported 2 ordinary shares held directly. It also reported 3,646 ordinary shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4zn4TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"gpt_icon":0},{"id":"2620823218","title":"Polyrizon Ltd. files Form 3 initial beneficial ownership statement for Director Carmel Liron","url":"https://stock-news.laohu8.com/highlight/detail?id=2620823218","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620823218?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:42","pubTimestamp":1773830536,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership filed by director Carmel Liron. The filing listed 2 ordinary shares beneficially owned directly. It also reported 4,167 ordinary shares beneficially owned directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9P2M6l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2620232187","title":"Polyrizon Ltd. files initial beneficial ownership statement for CTO Tidhar Turgeman","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232187","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232187?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:41","pubTimestamp":1773830480,"startTime":"0","endTime":"0","summary":"Tidhar Turgeman, Chief Technology Officer of Polyrizon, filed an initial statement of beneficial ownership dated 03/18/2026. He reported direct beneficial ownership of 18 ordinary shares. He also reported direct beneficial ownership of 20,417 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLJjXnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"gpt_icon":0},{"id":"2620617232","title":"Polyrizon Ltd. director Oz Adler files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620617232","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620617232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:40","pubTimestamp":1773830407,"startTime":"0","endTime":"0","summary":"Oz Adler, a director at Polyrizon, filed an initial statement of beneficial ownership dated 03/18/2026. The filing reported direct beneficial ownership of 100 ordinary shares. It also reported direct beneficial ownership of 23,042 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3JKYqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"gpt_icon":0},{"id":"2620232668","title":"Polyrizon Ltd. files Form 3 beneficial ownership statement for CEO Tomer Izraeli","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232668","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232668?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:39","pubTimestamp":1773830349,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership by Tomer Izraeli, its chief executive officer and a director. Izraeli reported direct beneficial ownership of 35,912 ordinary shares. Izraeli also reported options to purchase 88 ordinary shares at exercise prices of USD 1,699.3 and USD 1,700.3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3ZVdMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2620545232","title":"Polyrizon Ltd. CFO Nir BenYosef files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620545232","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620545232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:38","pubTimestamp":1773830290,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership for Nir BenYosef, its Chief Financial Officer. The filing shows BenYosef beneficially owned 732 ordinary shares directly. It also lists a direct option to purchase 2 ordinary shares with an exercise price of USD 1,699.3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1z1lc5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2620983422","title":"Polyrizon signs agreement with research organization for clinical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2620983422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620983422?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:35","pubTimestamp":1773750948,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) signed an agreement with a global preclinical Contract Research Organization, or CRO, an expert in biocompatibility and regulatory...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-signs-agreement-with-research-organization-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-signs-agreement-with-research-organization-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2620424201","title":"Polyrizon signs agreement with global preclinical CRO for ISO 10993 biocompatibility studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424201?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:25","pubTimestamp":1773750341,"startTime":"0","endTime":"0","summary":"Polyrizon signed an agreement with a global preclinical contract research organization to run biocompatibility studies under ISO 10993 and GLP requirements. The studies are expected to begin in Q2 2026 and include cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, and pyrogenicity assessments. CEO Tomer Izraeli said the work is intended to support regulatory submissions ahead of planned clinical trials later in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL1yjTww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4112","BK4585","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2W23.USD","BK4588","NDAQ","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014039.USD","PLRZ","IE00B64PRP62.GBP","BK4139"],"gpt_icon":0},{"id":"2620242274","title":"Polyrizon Signs an Agreement With Leading Global Preclinical Cro as Part of Clinical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242274?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:25","pubTimestamp":1773750300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA43MW7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2618937100","title":"Polyrizon Produces GMP Clinical Trial Material Batch With Eurofins CDMO AmatsiAquitaine","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937100","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937100?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143757,"startTime":"0","endTime":"0","summary":"Polyrizon said it successfully produced a Good Manufacturing Practice  batch of clinical trial material for its lead intranasal product candidate. The batch was manufactured with Eurofins CDMO AmatsiAquitaine and is intended to support a planned U.S. clinical study later this year. Polyrizon said the GMP batch followed two prior development batches that showed batch-to-batch consistency and product stability over time.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL6NFH0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4588","BK4585","SG9999014021.USD","SG9999014039.USD","BK4139","PLRZ","LU2210150020.SGD","SG9999014005.SGD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2618937903","title":"Polyrizon Announces Gmp Manufacturing of Clinical Trial Material (Ctm) With Eurofins CDMO Amatsiaquitaine S.a.s for Planned U.S. Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937903?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA5MXWMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2614421330","title":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2614421330","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614421330?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:28","pubTimestamp":1772112500,"startTime":"0","endTime":"0","summary":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug** Shares of drug developer Polyrizon PLRZ.O rise 5.2% to $14.25 premarket** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy** Shares down over 99% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4N3ZM1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2614044222","title":"Polyrizon Reports Study Showing Improved Nasal Deposition for Its Naloxone Formulation Versus Commercial Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044222","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044222?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:12","pubTimestamp":1772111555,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. reported results from a comparative study assessing the regional nasal deposition profile of its intranasal naloxone formulation versus a commercial reference product. Using a validated silicone nasal cast model with quantitative image analysis at the University of Parma’s Biopharmanet-TEC center, Polyrizon’s formulation showed 94.6%  deposition in the nasal vestibule and upper turbinate compared with 79.6%  for the reference product, and 5.4% deposition in the lower turbinate versus 20.4% for the reference. The results have already been presented in the company’s announcement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL13Nxj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","PLRZ","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2614044216","title":"Polyrizon Announces Successful Study of Its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044216?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:12","pubTimestamp":1772111520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA8NMLLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2612628286","title":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2612628286","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612628286?lang=en_us&edition=fundamental","pubTime":"2026-02-20 02:05","pubTimestamp":1771524345,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI , including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8bRMS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2610621072","title":"BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab","url":"https://stock-news.laohu8.com/highlight/detail?id=2610621072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610621072?lang=en_us&edition=fundamental","pubTime":"2026-02-10 23:41","pubTimestamp":1770738077,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, EcolabEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL6N3Z60ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2290526834.HKD","DD","GM","LU1815333072.USD","PSNL","KO","RGNX","MAS","ON","HOG","WTW","IE00BN8TJ469.HKD","LU0545039389.USD","ZBH","FLNC","CCO","CAT","HL","INCY","NKTR","RNG","TECX","HIMZ","MCHP","HIMY","VST","DDOG","LU1032466523.USD","PLRZ","MAR","DGX","HIMS","UPWK","HMYY","BK4196","OSCR","HAS","WMB","UAA","SPOT","LU1670710588.SGD","FTAI","J","CDE","ECL","WING","FDX","BDX","BK4585","WCC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":80,"code":"91000000","status":"200"}]}}